Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) has completed its rights offering, securing approximately $6.2 million. An additional $11.6 million may be raised through exercised warrants with a price of $0.50 per share. The offering led to 4,250 units sold, with specific purchase limits implemented for board vice chairman John K. Scott. The company plans a conference call on September 8, 2022, to discuss Q2 financial results and clinical developments.
- Rights offering raised approximately $6.2 million.
- Potential additional proceeds of up to $11.6 million through warrant exercise.
- Limited engagement from board vice chairman John K. Scott in the offering may raise concerns.
Conference Call to be Held on
Navidea received aggregate gross cash proceeds of approximately
The rights offering was made pursuant to the Company's registration statement on Form S-1, which was declared effective by the
The Company also announced it will host a conference call and webcast on
Dr.
To participate in the call and webcast, please refer to the information below:
Event: Second Quarter 2022 Earnings Conference Call and Business Update
Date:
Time:
International Dial-In: +1 201-389-0899
Conference ID: 13732617
Webcast Link: https://www.webcast-eqs.com/navidbioph20220908/en
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations, whether stated or implied, regarding our planned rights offering, financing plans and other future events. Words such as "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond our control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, among other things: our history of operating losses and ability to obtain additional financing; our ability to continue as a going concern; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005246/en/
Vice President of Operations
614-822-2365
jsmith@navidea.com
Source:
FAQ
What were the proceeds from Navidea's recent rights offering?
When is Navidea's conference call to discuss Q2 financial results?
What is the potential additional funding from warrants in Navidea's rights offering?